Lungex Liquid
NDC Package 44911-0439-1
Package Information
Lungex (ginkgo biloba, colon (suis), lung (suis), pancreas suis, germanium sesquioxide, cuprum metallicum, manganum metallicum, stannum metallicum, alpha-ketoglutaricum acidum, citricum acidum, fumaricum acidum, malic acid, pyruvic acid, succinicum acidum, naphthoquinone, arsenicum metallicum, calcarea carbonica, aconiticum acidum, cis, natrum oxalaceticum, phosphorus) liquids is lung, Large Intestine support****These statements are based upon traditional homeopathic practice. This formulation utilizes a liquid delivery system. Marketed by Energique, Inc., this product is identified by NDC 44911-0439.
Identification & Billing
Clinical Specifications
- 1,2-NAPHTHOQUINONE 9 [hp_X]/mL
- ACONITIC ACID 12 [hp_X]/mL
- ARSENIC 12 [hp_X]/mL
- CITRIC ACID MONOHYDRATE 8 [hp_X]/mL
- COPPER 8 [hp_X]/mL
- FUMARIC ACID 8 [hp_X]/mL
- GERMANIUM SESQUIOXIDE 8 [hp_X]/mL
- GINKGO 6 [hp_X]/mL
- MALIC ACID 8 [hp_X]/mL
- MANGANESE 8 [hp_X]/mL
- OXOGLURIC ACID 8 [hp_X]/mL
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X]/mL
- PHOSPHORUS 12 [hp_X]/mL
- PYRUVIC ACID 8 [hp_X]/mL
- SODIUM DIETHYL OXALACETATE 12 [hp_X]/mL
- SUCCINIC ACID 8 [hp_X]/mL
- SUS SCROFA COLON 6 [hp_X]/mL
- SUS SCROFA LUNG 6 [hp_X]/mL
- SUS SCROFA PANCREAS 6 [hp_X]/mL
- TIN 8 [hp_X]/mL
- Acidifying Activity - [MoA] (Mechanism of Action)
- Anti-coagulant - [EPC] (Established Pharmacologic Class)
- Calcium Chelating Activity - [MoA] (Mechanism of Action)
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Copper - [CS]
- Copper-containing Intrauterine Device - [EPC] (Established Pharmacologic Class)
- Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Decreased Embryonic Implantation - [PE] (Physiologic Effect)
- Decreased Sperm Motility - [PE] (Physiologic Effect)
- Inhibit Ovum Fertilization - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 44911 - Energique, Inc.
- 44911-0439 - Lungex
- 44911-0439-1 - 30 mL in 1 BOTTLE, DROPPER
- 44911-0439 - Lungex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 44911-0439-1 identifies a specific commercial package of 30 ml in 1 bottle, dropper of Lungex II, a human over the counter drug labeled by Energique, Inc.. This liquid is formulated for oral use and contains 1,2-naphthoquinone; aconitic acid; arsenic; citric acid monohydrate; copper; fumaric acid; germanium sesquioxide; ginkgo; malic acid; manganese; oxogluric acid; oyster shell calcium carbonate, crude; phosphorus; pyruvic acid; sodium diethyl oxalacetate; succinic acid; sus scrofa colon; sus scrofa lung; sus scrofa pancreas; tin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Energique, Inc. on September 08, 2017. The current certification is valid through December 31, 2026.
How is this Energique, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 44911043901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.